Yungjin Pharm Co Ltd (003520) - Total Liabilities

Latest as of September 2025: ₩156.23 Billion KRW ≈ $105.88 Million USD

Based on the latest financial reports, Yungjin Pharm Co Ltd (003520) has total liabilities worth ₩156.23 Billion KRW (≈ $105.88 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Yungjin Pharm Co Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.

Yungjin Pharm Co Ltd - Total Liabilities Trend (2013–2024)

This chart illustrates how Yungjin Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Yungjin Pharm Co Ltd balance sheet assets.

Yungjin Pharm Co Ltd Competitors by Total Liabilities

The table below lists competitors of Yungjin Pharm Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
UVAT Technology Co Ltd
TWO:3580
Taiwan NT$917.63 Million
ENIGMATIG LIMITED
NYSE MKT:EGG
USA $1.73 Million
United Utilities Group PLC
LSE:UU
UK GBX15.89 Billion
Grigeo AB
STU:WM8
Germany €76.06 Million
CASH CONVERTERS INTL
F:UKC
Germany €257.79 Million
Turk Prysmian Kablo ve Sistemleri AS
IS:PRKAB
Turkey TL8.63 Billion
Avita Medical Ltd
NASDAQ:RCEL
USA $73.04 Million
Diploma PLC
LSE:DPLM
UK GBX912.00 Million

Liability Composition Analysis (2013–2024)

This chart breaks down Yungjin Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Yungjin Pharm Co Ltd's balance sheet to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.20 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.74 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.63 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Yungjin Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Yungjin Pharm Co Ltd (2013–2024)

The table below shows the annual total liabilities of Yungjin Pharm Co Ltd from 2013 to 2024.

Year Total Liabilities Change
2024-12-31 ₩144.45 Billion
≈ $97.89 Million
+5.47%
2023-12-31 ₩136.97 Billion
≈ $92.82 Million
+20.98%
2022-12-31 ₩113.21 Billion
≈ $76.72 Million
+26.91%
2021-12-31 ₩89.21 Billion
≈ $60.46 Million
+21.10%
2020-12-31 ₩73.67 Billion
≈ $49.92 Million
-13.02%
2019-12-31 ₩84.69 Billion
≈ $57.40 Million
+0.22%
2018-12-31 ₩84.51 Billion
≈ $57.27 Million
+0.37%
2017-12-31 ₩84.20 Billion
≈ $57.06 Million
-9.65%
2016-12-31 ₩93.19 Billion
≈ $63.15 Million
-0.09%
2015-12-31 ₩93.27 Billion
≈ $63.21 Million
+19.30%
2014-12-31 ₩78.18 Billion
≈ $52.98 Million
+16.88%
2013-12-31 ₩66.89 Billion
≈ $45.33 Million
--

About Yungjin Pharm Co Ltd

KO:003520 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$126.67 Million
₩186.92 Billion KRW
Market Cap Rank
#18372 Global
#824 in Korea
Share Price
₩1022.00
Change (1 day)
+0.29%
52-Week Range
₩1019.00 - ₩2170.00
All Time High
₩17500.00
About

Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. It also provides vitamins, minerals, and other products; and APIs. The com… Read more